Skip to content
Screener

Retained Earnings at other companies

Labcorp Holdings logo
Labcorp HoldingsLH
$8.7B+2.4%
Rapid Micro Biosystems logo
Rapid Micro BiosystemsRPID
-$536.67M-10.3%
Sotera Health logo
Sotera HealthSHC
-$451.86M+26.6%
Ginkgo Bioworks logo
Ginkgo BioworksDNA
-$6.28B-4.9%
Fortrea Holdings Inc. logo
Fortrea Holdings Inc.FTRE
-$1.42B-6.4%
Revvity logo
RevvityRVTY
$6.09B+3.5%

Other financials

Income statement

See full
Revenue$1.0B-2.7%
Gross profit$349.0M-3.5%
Operating income$119.9M+19.7%
Net income-$1.5M-103%
EPS (diluted)-$0.03-103%

Balance sheet

See full
Cash & equivalents$240.6M+30.2%
Total debt$3.0B+8.1%
Total equity$2.8B-15.3%
Total assets$7.5B-0.4%

Cash flow

See full
Operating cash flow$179.7M-12.2%
CapEx$31.1M-11.9%
Free cash flow$148.6M-12.2%

Valuation

See full
Market cap$12.56B+70.1%
Enterprise value$15.36B+53.4%
P/S3.1×+1.3×

Profitability

See full
Gross margin84.7%
Operating margin13%-2.4pp
Net margin-6%
FCF margin9.3%-5.1pp

Returns & leverage

See full
Return on equity-7.7%
Debt / equity1.1×+0.2×
Current ratio1.3×0.0×

Where this comes from

Reported directly by Charles River Laboratories in its filing.

Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.

The source filing: Charles River Laboratories’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 9:21 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001100682-26-000118
Line itemJune 27, 2026December 27, 2025
Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding
Common stock, $0.01 par value; 120,000 shares authorized; 49,550 shares issued and 47,728 shares outstanding as of June 27, 2026, and 49,217 shares issued and outstanding as of December 27, 2025496492
Additional paid-in capital1,986,0231,947,301
Retained earnings1,372,2951,388,620
Treasury stock, at cost, 1,822 and zero shares, as of June 27, 2026 and December 27, 2025, respectively(323,189)
Accumulated other comprehensive loss(195,989)(171,783)
Total Charles River Laboratories International, Inc. equity2,839,6363,164,630
Nonredeemable noncontrolling interest6,3545,301

Item 1. Financial Statements

FAQ

What is Charles River Laboratories's retained earnings?
Charles River Laboratories (CRL) reported retained earnings of $1.37B in Q2 2026.
How has Charles River Laboratories's retained earnings changed year-over-year?
Charles River Laboratories's retained earnings decreased by 27.4% year-over-year, from $1.89B to $1.37B.
What is the long-term trend for Charles River Laboratories's retained earnings?
Over 5 years (2020 to 2025), Charles River Laboratories's retained earnings has grown at a 17.3% compound annual growth rate (CAGR), from $625.41M to $1.39B.
What does retained earnings mean?
Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.

Ask your AI about Charles River Laboratories's retained earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude